Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

Meta-analysis: DES Beneficial But May Not Save Limbs, Improve Survival in PAD Patients

May 03, 2013

News Daily News

Bailout DES Effective in CLI Patients with Below-the-Knee Lesions

April 19, 2013

News Daily News

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

April 12, 2013

News Daily News

PACIFIER Published: Drug-Eluting Balloon Helps Treat Femoropopliteal Lesions

Caitlin E. Cox

December 09, 2012

News Daily News

Los Refinamientos de la Braquiterapia arrojan Resultados Positivos en la Re-estenosis Intra-Stent

September 05, 2012

News Daily News

Brachytherapy Refinements Yield Positive Results in Peripheral In-Stent Restenosis

September 05, 2012

News Daily News

Restenotic Pattern After Femoropopliteal Stenting Predicts Recurrence

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

News Daily News

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

Jason Kahn

March 06, 2012

News Daily News

Zilver PTX: Novel DES for Femoropopliteal Disease Encouraging at 2 Years

January 17, 2011

Advertisement

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

Meta-analysis: DES Beneficial But May Not Save Limbs, Improve Survival in PAD Patients

Bailout DES Effective in CLI Patients with Below-the-Knee Lesions

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

PACIFIER Published: Drug-Eluting Balloon Helps Treat Femoropopliteal Lesions

Los Refinamientos de la Braquiterapia arrojan Resultados Positivos en la Re-estenosis Intra-Stent

Brachytherapy Refinements Yield Positive Results in Peripheral In-Stent Restenosis

Restenotic Pattern After Femoropopliteal Stenting Predicts Recurrence

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

Zilver PTX: Novel DES for Femoropopliteal Disease Encouraging at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content